US 12,172,994 B2
Pyrimidine compound as JAK kinase inhibitor
Jennifer Kozak, Pacifica, CA (US); Ryan Hudson, San Mateo, CA (US); Gary E. L. Brandt, Alameda, CA (US); Robert Murray McKinnell, Millbrae, CA (US); Marta Dabros, Foster City, CA (US); and Jerry Nzerem, South San Francisco, CA (US)
Assigned to THERAVANCE BIOPHARMA R&D IP, LLC, South San Francisco, CA (US)
Filed by THERAVANCE BIOPHARMA R&D IP, LLC, South San Francisco, CA (US)
Filed on Oct. 3, 2023, as Appl. No. 18/480,442.
Application 18/480,442 is a continuation of application No. 17/855,539, filed on Jun. 30, 2022, granted, now 11,814,377, issued on Nov. 14, 2023.
Application 17/855,539 is a continuation of application No. 17/301,243, filed on Mar. 30, 2021, granted, now 11,420,965, issued on Aug. 23, 2022.
Application 17/301,243 is a continuation of application No. 16/991,268, filed on Aug. 12, 2020, granted, now 10,988,470, issued on Apr. 27, 2021.
Application 16/991,268 is a continuation of application No. 16/737,067, filed on Jan. 8, 2020, granted, now 10,774,080, issued on Sep. 15, 2020.
Application 16/737,067 is a continuation of application No. 16/390,175, filed on Apr. 22, 2019, granted, now 10,562,894, issued on Feb. 18, 2020.
Application 16/390,175 is a continuation of application No. 16/171,693, filed on Oct. 26, 2018, granted, now 10,308,646, issued on Jun. 4, 2019.
Claims priority of provisional application 62/577,852, filed on Oct. 27, 2017.
Prior Publication US 2024/0158389 A1, May 16, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 451/14 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 31/506 (2006.01); A61K 45/06 (2006.01); A61P 17/00 (2006.01); A61P 17/14 (2006.01); A61P 37/06 (2006.01); C07D 403/12 (2006.01); C07D 451/04 (2006.01)
CPC C07D 451/14 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 31/506 (2013.01); A61K 45/06 (2013.01); A61P 17/00 (2018.01); A61P 17/14 (2018.01); A61P 37/06 (2018.01); C07D 403/12 (2013.01); C07D 451/04 (2013.01); C07B 2200/13 (2013.01)] 19 Claims
 
1. A crystalline form of the compound of formula (I):

OG Complex Work Unit Chemistry
wherein the crystalline form is characterized by a powder X-ray diffraction pattern comprising diffraction peaks at 2θ values of 11.4±0.2 and 21.9±0.2.